Stiripentol - Biocodex

Drug Profile

Stiripentol - Biocodex

Alternative Names: BCX 2600; Diacomit; ME-2080

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocodex
  • Developer Biocodex; Meiji Seika Pharma
  • Class Antiepileptic drugs; Dioxolanes; Neuroprotectants
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myoclonic epilepsies

Most Recent Events

  • 17 Aug 2017 Biocodex completes a phase II trial for Myoclonic epilepsies in France
  • 31 Jan 2012 Preregistration for Myoclonic epilepsies in Japan (PO, capsule)
  • 31 Jan 2012 Preregistration for Myoclonic epilepsies in Japan (PO, suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top